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Abstract  
Isolated peritoneal metastases of lung adenocarcinoma are very rare, even exceptional, occurring most often in the context of a multi-metastatic 
disease. This report presents a rare clinical case of isolated peritoneal metastasis from lung adenocarcinoma. We report a 56-year-old male who 
was monitored for lung adenocarcinoma whose evolution has been marked by an isolated metastatic recurrence in the peritoneum objectified by 
an abdominal-pelvic computed tomography (CT) and confirmed by a laparoscopy with abiopsy of the peritoneal nodules. The patient had received 
palliative chemotherapy with gemcitabine, cisplatin and bevacizumab. The evolution was marked by a progressive deterioration of the general 
condition and death two months after the third treatment cycle. Peritoneal carcinomatosis from lung adenocarcinoma is a very rare event, and is 
often associated with a poor prognosis. 
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Introduction 
 
Lung cancer is the world's most frequently diagnosed cancer (1.82 
million) and the leading cause of cancer related death (1.6 million 
deaths) [1]. Conventional metastatic sites are the liver, adrenal 
glands, the brain and bone. Isolated peritoneal metastasis is a very 
rare event. This report presents a rare clinical case of isolated 
peritoneal metastasis from lung adenocarcinoma. 
  
  
Patient and observation 
 
A 56-year old male, with history of chronic smoking, was monitored 
from 2011 for a lung adenocarcinoma, initially classified as stage 
IIIA (pT2N3M0). The patient underwent a right upper lobectomy 
with lymph node dissection in January 2011. Adjuvant 
chemotherapy with paclitaxel and carboplatin was administered in 4 
cycles until June 2011. In March 2012, he had abdominal pain. The 
abdominal-pelvic ultrasound showed small amounts of ascites. The 
hepatitis B and C serologies were normal, liver function tests and 
blood counts were normal. The chest and abdominal-pelvic 
computed tomography (CT) showed the presence of a moderate 
amount of ascites without obvious signs of lung relapse or 
abdominal visceral disease. Bone scan and brain CT were both 
normal. An ultrasound-guided puncture was attempted twice 
without success. The patient underwent exploratory laparoscopy 
which showed nodules of peritoneal carcinomatosis with a moderate 
amount of ascites. A biopsy of the peritoneal nodules was 
performed. The histological examination revealed adenocarcinoma. 
The immunohistochemistry showed that the carcinoma cells were 
positive for cytokeratin 7 (CK7) (Figure 1) and thyroid transcription 
factor-1 (TT1) (Figure 2) and negative for cytokeratin 20 (CK20) 
(Figure 3). Those immunohistological findings suggested the tumor 
to be metastatic from the primary lung adenocarcinoma. Genotyping 
of epidermal growth factor receptor (EGFR) exons 18 to 21 did not 
show any detectable mutation. The patient underwent palliative 
chemotherapy following the gemcitabine, cisplatin and bevacizumab 
protocol. The evolution was marked by a progressive deterioration 







Preferential metastases sites for lung cancer are the liver, adrenal 
glands, the brain and bone. While abdominal visceral metastases 
have been reported in the context of lung cancer [2-4], isolated 
peritoneal metastasis is a very rare event, most often described in 
old autopsy series [5]. It can occur in the context of a multi-organ 
metastasis and is only exceptionally indicative of a primary lung 
tumor. Satoh et al reviewed the observations of 1041 patients 
treated consecutively between 1976 and 2001; 12 patients (1.2%) 
developed peritoneal involvement over the course of the disease. 
Six and nine of the twelve patients had abdominal visceral 
metastases and pleural metastasis, respectively [6]. The frequency 
of the peritoneal metastasis was higher in the case of 
adenocarcinoma and large cell carcinoma. Other cases of peritoneal 
carcinomatosis of lung cancer have been reported in the literature 
but the majority of patients had advanced disease with multiple 
metastatic sites [7]. The tumors that most often accompany 
peritoneal disease are those of the ovary and the gastrointestinal 
tract [8]. Three implantation mechanisms of the tumor cells on the 
peritoneum have been described in the literature [9]; by contiguity 
expansion secondary to the involvement of the serosa and its 
supersession by the tumor resulting in exfoliation of tumor cells in 
the peritoneal cavity, where they are likely to take hold; iatrogenic 
expansion which may be secondary to the direct trauma of the 
tumor during its removal from where tumor cells circulate in the 
veins and lymph nodes severed during removal of the tumor. 
Systemic expansion is rare and can occur for a number of digestive 
and non-digestive cancers but at an advanced stage of development 
(breast, lungs, etc.). However, the mechanism of the isolated 
peritoneal dissemination of a lung cancer has not been studied [6]. 
Clinically, peritoneal carcinomatosis is usually asymptomatic at the 
early stage, making its detection less likely. In recent years, with 
the development and availability of new imaging techniques such as 
CT and PET scans, peritoneal carcinomatosis can be diagnosed more 
easily and accurately. In our case the diagnosis was confirmed by a 
diagnostic laparoscopy with biopsy of the peritoneal nodules. The 
immunohistochemistry usually comprises CK5/6, TTF1, CK7 and 
CK20. In our case, the immunophynotype of CK7 positive, CK20 
negative and TTF1 positive makes the primitive nature of the lung 
cancer almost certain [10]. Despite recent medical and surgical 
advances, the treatment of peritoneal carcinomatosis is primarily 
palliative and the survival median is no more than two months [6,7]. 
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Conclusion 
 
Peritoneal carcinomatosis from lung cancer remains a rare event. 
This diagnosis should always be considered for the occurrence of 
unexplained abdominal symptoms, especially in a patient already 
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Figure 1: Biopsy of the peritoneal nodules shows positive staining 
CK7 on immunohistochemistry 
Figure 2: Biopsy of the peritoneal nodules shows positive staining 
TTF1 on immunohistochemistry 
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Figure 3: Biopsy of the peritoneal nodules: CK20 negative on 
immunohistochemistry 
 
